{"id":68954,"date":"2024-06-13T09:34:20","date_gmt":"2024-06-13T14:34:20","guid":{"rendered":"https:\/\/www.partnershipagainstcancer.ca\/topics\/breast-indicators-2018-2021\/key-takeaways\/"},"modified":"2024-06-13T14:55:21","modified_gmt":"2024-06-13T19:55:21","slug":"key-takeaways","status":"publish","type":"topics","link":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/","title":{"rendered":"Principaux points \u00e0 prendre en consid\u00e9ration"},"content":{"rendered":"<p>Il existe des variations dans les r\u00e9sultats des indicateurs entre les programmes de d\u00e9pistage du cancer du sein des diff\u00e9rents territoires de comp\u00e9tence du Canada. Bien que plusieurs succ\u00e8s aient \u00e9t\u00e9 signal\u00e9s pour l\u2019ensemble des programmes, les donn\u00e9es mettent \u00e9galement en \u00e9vidence des occasions d\u2019am\u00e9lioration.<\/p>\n<ul>\n<li>Dans l\u2019ensemble, les programmes de d\u00e9pistage du cancer du sein continuent de d\u00e9ployer des efforts importants pour am\u00e9liorer la qualit\u00e9 et la prestation des services de d\u00e9pistage suite aux d\u00e9fis pr\u00e9sent\u00e9s par la pand\u00e9mie de COVID-19. L\u2019incidence de la pand\u00e9mie de COVID-19 sur le d\u00e9pistage du cancer du sein a \u00e9t\u00e9 consid\u00e9rable, augmentant les disparit\u00e9s existantes. Les donn\u00e9es actuelles sont limit\u00e9es dans leur capacit\u00e9 \u00e0 fournir un aper\u00e7u de la nature de ces disparit\u00e9s. La pand\u00e9mie a eu des r\u00e9percussions notables sur les taux de participation au d\u00e9pistage dans tous les territoires de comp\u00e9tence, ce qui constitue un revers pour atteindre la cible nationale de\u00a070\u00a0%. Les territoires de comp\u00e9tence continuent de mettre en \u0153uvre des strat\u00e9gies adapt\u00e9es \u00e0 l\u2019ensemble de la population pour r\u00e9tablir les quantit\u00e9s de d\u00e9pistage apr\u00e8s la pand\u00e9mie et atteindre les populations mal desservies. Pour de plus amples renseignements, veuillez consulter l\u2019analyse de l\u2019environnement <a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-cancer-screening-in-canada-2021-2022\/summary\/\">D\u00e9pistage du cancer du sein au Canada\u00a0:\u00a02021-2022<\/a>. La <a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/about-us\/corporate-resources-publications\/pan-canadian-cancer-data-strategy\/\" rel=\"noopener\">Strat\u00e9gie pancanadienne de donn\u00e9es sur le cancer (SPDC)<\/a> a fix\u00e9 comme priorit\u00e9 cl\u00e9 de garantir la disponibilit\u00e9 de donn\u00e9es de qualit\u00e9 \u00e9lev\u00e9e, en vue de mieux comprendre les disparit\u00e9s entre les territoires de comp\u00e9tence.<\/li>\n<li><strong>Le taux de rappel pour anomalie d\u00e9passe toujours l\u2019objectif<\/strong> et continue d\u2019\u00eatre un domaine d\u2019optimisation des programmes dans tous les territoires de comp\u00e9tence. Le recours aux strat\u00e9gies d\u00e9crites dans le <strong><a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Framework-for-action-ACR-breast-screening-FR.pdf\" target=\"_blank\" rel=\"noopener\">Cadre d\u2019action pancanadien pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein<\/a><\/strong> permettra aux programmes de d\u00e9pistage d\u2019optimiser leurs taux de rappel pour anomalie, r\u00e9duisant ainsi potentiellement les m\u00e9faits associ\u00e9s au surd\u00e9pistage et aux analyses de suivi inutiles.<\/li>\n<li>On observe une <strong>am\u00e9lioration de la valeur pr\u00e9dictive positive<\/strong> dans tout le pays, la<strong> plupart des territoires de comp\u00e9tence atteignant la cible (&gt;\u00a06\u00a0%) pour les d\u00e9pistages subs\u00e9quents<\/strong>, ce qui sugg\u00e8re que les analyses de d\u00e9pistage ont une plus grande probabilit\u00e9 de d\u00e9tecter v\u00e9ritablement la maladie. Des am\u00e9liorations sont encore possibles pour atteindre la cible, pour les d\u00e9pistages initiaux.<\/li>\n<li>Les d\u00e9lais d\u2019attente pour un diagnostic d\u00e9finitif variaient selon les territoires de comp\u00e9tence. La plupart des territoires de comp\u00e9tence n\u2019ont pas atteint la cible nationale concernant le pourcentage de personnes recevant un diagnostic d\u00e9finitif dans un d\u00e9lai de cinq ou sept semaines (selon qu\u2019une biopsie \u00e9tait n\u00e9cessaire ou non). Les r\u00e9sultats observ\u00e9s pourraient \u00eatre en partie attribu\u00e9s aux interruptions des services de d\u00e9pistage et de diagnostic d\u00e9coulant de la pand\u00e9mie de COVID-19.<\/li>\n<li>Tous les territoires de comp\u00e9tence ont atteint la cible en mati\u00e8re de taux de d\u00e9tection de cancers pour les d\u00e9pistages initiaux et subs\u00e9quents.<\/li>\n<\/ul>\n<p>La surveillance et l\u2019\u00e9valuation d\u2019indicateurs communs \u00e0 l\u2019\u00e9chelle du syst\u00e8me pancanadien nous permettent de mieux comprendre comment les programmes de d\u00e9pistage provinciaux et territoriaux r\u00e9pondent aux besoins de la population cible, mettent en \u0153uvre des strat\u00e9gies d\u2019am\u00e9lioration de l\u2019acc\u00e8s pour les populations mal desservies et vont de l\u2019avant en innovant apr\u00e8s la pand\u00e9mie de COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Il existe des variations dans les r\u00e9sultats des indicateurs entre les programmes de d\u00e9pistage du cancer du sein des diff\u00e9rents territoires de comp\u00e9tence du Canada. Bien que plusieurs succ\u00e8s aient \u00e9t\u00e9 signal\u00e9s pour l\u2019ensemble des programmes, les donn\u00e9es mettent \u00e9galement en \u00e9vidence des occasions d\u2019am\u00e9lioration. Dans l\u2019ensemble, les programmes de d\u00e9pistage du cancer du sein [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":68573,"menu_order":3,"template":"","topics_tags":[],"type-of-care":[],"cancer-continuum":[],"cancer-system-measurement":[],"dbt-cancer-site":[],"dbt-risk-factors":[],"dbt-population-characteristics":[],"class_list":["post-68954","topics","type-topics","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canadian Partnership Against Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Principaux points \u00e0 prendre en consid\u00e9ration - Canadian Partnership Against Cancer\" \/>\n<meta property=\"og:description\" content=\"Il existe des variations dans les r\u00e9sultats des indicateurs entre les programmes de d\u00e9pistage du cancer du sein des diff\u00e9rents territoires de comp\u00e9tence du Canada. Bien que plusieurs succ\u00e8s aient \u00e9t\u00e9 signal\u00e9s pour l\u2019ensemble des programmes, les donn\u00e9es mettent \u00e9galement en \u00e9vidence des occasions d\u2019am\u00e9lioration. Dans l\u2019ensemble, les programmes de d\u00e9pistage du cancer du sein [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Partnership Against Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-13T19:55:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@cancerstratca\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/key-takeaways\\\/\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/key-takeaways\\\/\",\"name\":\"Principaux points \u00e0 prendre en consid\u00e9ration - Canadian Partnership Against Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\"},\"datePublished\":\"2024-06-13T14:34:20+00:00\",\"dateModified\":\"2024-06-13T19:55:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/key-takeaways\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/key-takeaways\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/key-takeaways\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Topics\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/topics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Surveillance et \u00e9valuation des indicateurs de la qualit\u00e9 du d\u00e9pistage du cancer du sein\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/breast-indicators-2018-2021\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Principaux points \u00e0 prendre en consid\u00e9ration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\",\"url\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/\",\"name\":\"Canadian Partnership Against Cancer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canadian Partnership Against Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/","og_locale":"fr_FR","og_type":"article","og_title":"Principaux points \u00e0 prendre en consid\u00e9ration - Canadian Partnership Against Cancer","og_description":"Il existe des variations dans les r\u00e9sultats des indicateurs entre les programmes de d\u00e9pistage du cancer du sein des diff\u00e9rents territoires de comp\u00e9tence du Canada. Bien que plusieurs succ\u00e8s aient \u00e9t\u00e9 signal\u00e9s pour l\u2019ensemble des programmes, les donn\u00e9es mettent \u00e9galement en \u00e9vidence des occasions d\u2019am\u00e9lioration. Dans l\u2019ensemble, les programmes de d\u00e9pistage du cancer du sein [&hellip;]","og_url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/","og_site_name":"Canadian Partnership Against Cancer","article_publisher":"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/","article_modified_time":"2024-06-13T19:55:21+00:00","twitter_card":"summary_large_image","twitter_site":"@cancerstratca","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/","url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/","name":"Principaux points \u00e0 prendre en consid\u00e9ration - Canadian Partnership Against Cancer","isPartOf":{"@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website"},"datePublished":"2024-06-13T14:34:20+00:00","dateModified":"2024-06-13T19:55:21+00:00","breadcrumb":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/key-takeaways\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Topics","item":"https:\/\/www.partnershipagainstcancer.ca\/topics\/"},{"@type":"ListItem","position":2,"name":"Surveillance et \u00e9valuation des indicateurs de la qualit\u00e9 du d\u00e9pistage du cancer du sein","item":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/breast-indicators-2018-2021\/"},{"@type":"ListItem","position":3,"name":"Principaux points \u00e0 prendre en consid\u00e9ration"}]},{"@type":"WebSite","@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website","url":"https:\/\/dev.partnershipagainstcancer.ca\/","name":"Canadian Partnership Against Cancer","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.partnershipagainstcancer.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/68954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/types\/topics"}],"author":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/users\/24"}],"up":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/68573"}],"wp:attachment":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=68954"}],"wp:term":[{"taxonomy":"topics_tags","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics_tags?post=68954"},{"taxonomy":"type-of-care","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/type-of-care?post=68954"},{"taxonomy":"cancer-continuum","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-continuum?post=68954"},{"taxonomy":"cancer-system-measurement","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-system-measurement?post=68954"},{"taxonomy":"dbt-cancer-site","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-cancer-site?post=68954"},{"taxonomy":"dbt-risk-factors","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-risk-factors?post=68954"},{"taxonomy":"dbt-population-characteristics","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-population-characteristics?post=68954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}